Table 1.
Definitions of metabolic (MAFLD framework) and cardiometabolic (MASLD framework) risk factors
| *Definitions of metabolic risk factors within the MAFLD framework |
**Definitions of cardiometabolic risk factors within the MASLD framework |
|---|---|
| Waist circumference ≥102/88 cm or ≥94/80 cm (AHA/NHLBI) in Caucasian men and women or ≥90/80 cm in Asian men and women) | Body mass index ≥25 kg/m2 (23 kg/m2 in Asian individuals) OR waist circumference >94 cm (men) >80 cm (women) OR ethnicity-adjusted values (≥95 cm [men] ≥91 cm [women] in Türkiye) |
| Blood pressure ≥130/85 mm Hg or specific drug treatment | Blood pressure ≥130/85 mm Hg OR specific antihypertensive drug treatment |
| Plasma triglycerides ≥150 mg/dL (≥1.70 mmol/L) or specific drug treatment | Plasma triglycerides ≥150 mg/dL (≥1.70 mmol/L) OR lipid lowering treatment |
| Plasma HDL-cholesterol <40 mg/dL (<1.0 mmol/L) for men and <50 mg/dL (<1.3 mmol/L) for women or specific drug treatment | Plasma HDL-cholesterol ≤40 mg/dL (<1.0 mmol/L) (men) and ≤50 mg/dL (<1.3 mmol/L) (women) OR lipid-lowering treatment |
| Pre-diabetes (i.e., fasting glucose levels 100 to 125 mg/dL [5.6–6.9 mmol/L], or 2-h post-load glucose levels 140–199 mg/dL [7.8–11.0 mmol/L] or HbA1c 5.7–6.4% [39–47 mmol/L]) | Fasting serum glucose ≥ 100 mg/dL [5.6 mmol/L) OR 2-h post-load glucose levels ≥ 140 mg/dL [7.8 mmol/L] OR HbA1c ≥ 5.7% [39 mmol/L]) OR Type 2 diabetes OR treatment for Type 2 diabetes |
| Homeostasis model assessment of insulin resistance score ≥2.5 | |
| Plasma high-sensitivity C-reactive protein level >2 mg/L |
MAFLD: Metabolic (dysfunction) associated fatty liver disease, MASLD: Metabolic dysfunction-associated steatotic liver disease, AHA: American heart association, NHLBI: National heart, Lung, and Blood Institute, HDL: High-density lipoprotein.